CDK12

Cyclin-dependent kinase 12

54,024 patent compounds predicted against CDK12, 30,160 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL268925	0.50	18/20
SCHEMBL269583	0.50	18/20
SCHEMBL517413	0.54	12/20
SCHEMBL517461	0.54	11/20
SCHEMBL559356	0.51	11/20
SCHEMBL517664	0.48	8/20
SCHEMBL99955	0.56	7/20
SCHEMBL102731	0.53	7/20
SCHEMBL559412	0.50	7/20
SCHEMBL559413	0.50	7/20
SCHEMBL99686	0.47	7/20
SCHEMBL559189	0.47	7/20
SCHEMBL558710	0.45	7/20
SCHEMBL558711	0.45	7/20
SCHEMBL559506	0.45	7/20
SCHEMBL559507	0.45	7/20
Seliciclib (SCHEMBL94728)	1.00	6/20
(Rs)-Roscovitine (SCHEMBL172593)	1.00	6/20
SCHEMBL558222	0.49	6/20
SCHEMBL558223	0.49	6/20

Germline variants in CDK12 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK12 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations	PHASE2	COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation	PHASE2	ACTIVE_NOT_RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer	PHASE1/PHASE2	NOT_YET_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer	PHASE2	COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer	PHASE2	WITHDRAWN
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer	PHASE2	RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO	PHASE2	COMPLETED
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)	PHASE2	ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors	PHASE1	COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK12 binder may also engage these)

Protein	Name	Similarity
E1BB50	—	1.000	E1BB50 →
Q14AX6	—	1.000	Q14AX6 →
Q3MJK5	—	1.000	Q3MJK5 →
B5DE93	—	0.999	B5DE93 →
D2H526	—	0.997	D2H526 →
Q24595	—	0.993	Q24595 →
Q9HCH5	—	0.992	Q9HCH5 →
Q6UB99	—	0.992	Q6UB99 →
Q3UTQ8	—	0.992	Q3UTQ8 →
Q9NRR4	—	0.992	Q9NRR4 →
Q9VP22	—	0.992	Q9VP22 →
Q5HZJ0	—	0.991	Q5HZJ0 →
B0BN49	—	0.991	B0BN49 →
CCNT2	Cyclin-T2	0.991	landscape →
P97868	—	0.991	P97868 →
P30415	—	0.991	P30415 →
TNIK	TRAF2 and NCK-interacting protein kinase	0.991	landscape →
Q9P2R6	—	0.991	Q9P2R6 →
Q498L0	—	0.991	Q498L0 →
Q9JKV2	—	0.991	Q9JKV2 →
A7MBB4	—	0.991	A7MBB4 →
MAP4K4	Mitogen-activated protein kinase kinase kinase kinase 4	0.991	landscape →
P46551	—	0.991	P46551 →
A2AM29	—	0.991	A2AM29 →
Q90YL3	—	0.990	Q90YL3 →
A2RUV4	—	0.990	A2RUV4 →
Q6H7U2	—	0.990	Q6H7U2 →
Q95XU6	—	0.990	Q95XU6 →
KAT6B	Histone acetyltransferase KAT6B	0.990	landscape →
Q9H329	—	0.989	Q9H329 →